Our work demonstrate that the persistent signaling by mutated EGFR in TKI‐resistant tumor cells relies on palmitoylation of EGFR and can be targeted by Orlistat, an FDA‐approved anti‐obesity drug. The gene discussed is EGFR; the disease is obesity disorder.